LEXXEL Drug Patent Profile
✉ Email this page to a colleague
When do Lexxel patents expire, and when can generic versions of Lexxel launch?
Lexxel is a drug marketed by Astrazeneca and is included in one NDA.
The generic ingredient in LEXXEL is enalapril maleate; felodipine. There are twenty-seven drug master file entries for this compound. Additional details are available on the enalapril maleate; felodipine profile page.
Summary for LEXXEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 55 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LEXXEL at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for LEXXEL
US Patents and Regulatory Information for LEXXEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | LEXXEL | enalapril maleate; felodipine | TABLET, EXTENDED RELEASE;ORAL | 020668-002 | Oct 28, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Astrazeneca | LEXXEL | enalapril maleate; felodipine | TABLET, EXTENDED RELEASE;ORAL | 020668-001 | Dec 27, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LEXXEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca | LEXXEL | enalapril maleate; felodipine | TABLET, EXTENDED RELEASE;ORAL | 020668-001 | Dec 27, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Astrazeneca | LEXXEL | enalapril maleate; felodipine | TABLET, EXTENDED RELEASE;ORAL | 020668-001 | Dec 27, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Astrazeneca | LEXXEL | enalapril maleate; felodipine | TABLET, EXTENDED RELEASE;ORAL | 020668-002 | Oct 28, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LEXXEL
See the table below for patents covering LEXXEL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Algeria | 1067 | Nouvelles préparations pharmaceutiques à emission prolongée. | ⤷ Try a Trial |
| Australia | 5346179 | ⤷ Try a Trial | |
| Romania | 85071 | PROCEDEU PENTRU PREPARAREA UNUI DERIVAT DE ALANILPROLINA (PROCESS FOR THE PREPARATION OF ALANYLPROLINE DERIVATIVE) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LEXXEL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0007293 | 95C0001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: FELODIPINE, METOPOLOL SUCCINATE; NAT. REGISTRATION NO/DATE: 122 IS 160 F 3 / 19921230; FIRST REGISTRATION: DK 8678 19921230 |
| 0007293 | SPC/GB93/134 | United Kingdom | ⤷ Try a Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
